Page 51 - GTM-3-3

Global Translational Medicine Ocular changes in Alzheimer’s disease

(Amst). 2017;8:11-17. mice. PLoS One. 2012;7(12):e5347.
doi: 10.1016/j.dadm.2017.03.004 doi: 10.1371/journal.pone.0053547
27. Podoleanu AG, Rosen RB. Combinations of techniques in 38. Ho C, Troncoso JC, Knox D, Stark W, Eberhart CG.
imaging the retina with high resolution. Prog Retin Eye Res. Beta‐amyloid, phospho‐tau and alpha‐synuclein deposits
2008;27(4):464-499. similar to those in the brain are not identified in the eyes of
Alzheimer’s and Parkinson’s disease patients. Brain Pathol.
doi: 10.1016/j.preteyeres.2008.03.002
2014;24(1):25-32.
28. Puyo L, Paques M, Fink M, Sahel JA, Atlan M. In vivo laser
Doppler holography of the human retina. Biomed Opt doi: 10.1111/bpa.12070
Express. 2018;9(9):4113. 39. Den Haan J, Morrema THJ, Verbraak FD, et al. Amyloid-
beta and phosphorylated tau in post-mortem Alzheimer’s
doi: 10.1364/BOE.9.004113
disease retinas. Acta Neuropathol Commun. 2018;6(1):147.
29. Salobrar-Garcia E, Méndez-Hernández C, Hoz R, et al.
Ocular vascular changes in mild Alzheimer’s disease doi: 10.1186/s40478-018-0650-x
patients: Foveal avascular zone, choroidal thickness, and 40. Chiasseu M, Alarcon-Martinez L, Belforte N, et al. Tau
ONH hemoglobin analysis. J Pers Med. 2020;10(4):231. accumulation in the retina promotes early neuronal
dysfunction and precedes brain pathology in a mouse model
doi: 10.3390/jpm10040231
of Alzheimer’s disease. Mol Neurodegener. 2017;12(1):58.
30. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL.
Retinal abnormalities in early Alzheimer’s disease. Invest doi: 10.1186/s13024-017-0199-3
Ophthalmol Vis Sci. 2007;48(5):2285-2289. 41. Hart de Ruyter FJ, Morrema THJ, den Haan J, et al.
Phosphorylated tau in the retina correlates with tau
doi: 10.1167/iovs.06-1029
pathology in the brain in Alzheimer’s disease and primary
31. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. tauopathies. Acta Neuropathol. 2023;145(2):197-218.
Identification of amyloid plaques in retinas from Alzheimer’s
patients and noninvasive in vivo optical imaging of retinal doi: 10.1007/s00401-022-02525-1
plaques in a mouse model. Neuroimage. 2011;54:S204-S217. 42. Ballatore C, Lee VMY, Trojanowski JQ. Tau-mediated
neurodegeneration in Alzheimer’s disease and related
doi: 10.1016/j.neuroimage.2010.06.020
disorders. Nat Rev Neurosci. 2007;8(9):663-672.
32. Tadokoro K, Yamashita T, Kimura S, et al. Retinal amyloid doi: 10.1038/nrn2194
imaging for screening Alzheimer’s disease. J Alzheimer Dis.
2021;83(2):927-934. 43. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R,
Hugon J. Abnormal retinal thickness in patients with mild
doi: 10.3233/JAD-210327
cognitive impairment and Alzheimer’s disease. Neurosci
33. Lee S, Jiang K, McIlmoyle B, et al. Amyloid beta Lett. 2007;420(2):97-99.
immunoreactivity in the retinal ganglion cell layer of the doi: 10.1016/j.neulet.2007.02.090
Alzheimer’s eye. Front Neurosci. 2020;14:758.
44. He XF, Liu YT, Peng C, Zhang F, Zhuang S, Zhang JS.
doi: 10.3389/fnins.2020.00758
Optical coherence tomography assessed retinal nerve fiber
34. Kitazawa M, Medeiros R, LaFerla F. Transgenic mouse layer thickness in patients with Alzheimer’s disease: A meta-
models of Alzheimer disease: Developing a better model analysis. Int J Ophthalmol. 2012;5(3):401-405.
as a tool for therapeutic interventions. Curr Pharm Des. doi: 10.3980/j.issn.2222-3959.2012.03.30
2012;18(8):1131-1147.
45. Gao L, Liu Y, Li X, Bai Q, Liu P. Abnormal retinal nerve
doi: 10.2174/138161212799315786
fiber layer thickness and macula lutea in patients with
35. Koronyo Y, Rentsendorj A, Mirzaei N, et al. Retinal mild cognitive impairment and Alzheimer’s disease. Arch
pathological features and proteome signatures of Alzheimer’s Gerontol Geriatr. 2015;60(1):162-167.
disease. Acta Neuropathol. 2023;145(4):409-438.
doi: 10.1016/j.archger.2014.10.011
doi: 10.1007/s00401-023-02548-2
46. Garcia‐Martin E, Bambo MP, Marques ML, et al. Ganglion
36. Tsai Y, Lu B, Ljubimov AV, et al. Ocular changes in cell layer measurements correlate with disease severity
TgF344-AD rat model of Alzheimer’s disease. Invest in patients with Alzheimer’s disease. Acta Ophthalmol.
Opthalmol Vis Sci. 2014;55(1):523-534. 2016;94(6):e454-e459.
doi: 10.1167/iovs.13-12888 doi: 10.1111/aos.12977
37. Schön C, Hoffmann NA, Ochs SM, et al. Long-term in vivo 47. Chiquita S, Campos EJ, Castelhano J, et al. Retinal thinning
imaging of fibrillar tau in the retina of P301S transgenic of inner sub-layers is associated with cortical atrophy in

Volume 3 Issue 3 (2024) 12 doi: 10.36922/gtm.4094